The chief executive of German stock exchange operator Deutsche Boerse has resigned amid an investigation into potential insider trading.
The company’s board announced Carsten Kengeter’s departure on Thursday, October 26, just days after a German court turned down a settlement offer that would have closed the investigation.
Prosecutors in Frankfurt have been probing Kengeter’s purchase of Deutsche Boerse shares worth €4.5 million (US$5.3 million) in December 2015, just weeks before his firm began merger talks with the London Stock Exchange.
Plans to combine the companies were announced in February 2016, and shares in both firms soared as a result. The deal was blocked by the European Union’s competition watchdog in March.
Deutsche Boerse said earlier this year that Kengeter was allowed to buy the shares as part his official remuneration program, which was approved by its supervisory board.
The board, which had been publicly supportive of Kengeter, said Thursday that it had accepted his resignation with “deep regret.” He will leave his post at the end of 2017.
Deutsche Boerse said in September that it had agreed a €10.5 million (US$12.3 million) settlement with prosecutors that would have closed the investigation. The deal required Kengeter to personally pay an additional €500,000 (US$585,000).
Full Content: US News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas